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Abstract 
Non-specific effects (NSE) or heterologous effects of vaccines are proposed to explain observations in 
some studies that certain vaccines have an impact beyond the direct protection against infection 
with the specific pathogen for which the vaccines were designed. The importance and implications of 
such effects remain controversial. There are several known immunological mechanisms which could 
lead to NSE, since it is widely recognised that the generation of specific immunity is initiated by non-
specific innate immune mechanisms that may also have wider effects on adaptive immune function. 
However, there are no published studies that demonstrate a mechanistic link between such 
immunological phenomena and clinically relevant NSE in humans. Whilst it is highly plausible that 
some vaccines do have NSE, their magnitude and duration, and thus importance, remain uncertain. 
Although the WHO recently concluded that current evidence does not justify changes to 
immunisation policy, further studies of sufficient size and quality are needed to assess the 
importance of NSE and the effects of different sequences of vaccinations on all-cause mortality. This 
could provide insights into vaccine immunobiology with important implications for infant health and 
survival.   
Introduction 
In 1974, the World Health Organization (WHO) recommended six vaccines (diphtheria, pertussis, 
tetanus, measles, poliomyelitis and tuberculosis) for immunisation of infants, with a target set in 
1977 that this Expanded Programme on Immunization (EPI) should reach all children by 1990 
(www.who.int/immunization/programmes_systems/supply_chain/benefits_of_immunization/en/). 
Despite considerable progress, that goal has not yet been achieved, but today more than 85% of 
children receive these vaccines and many others, including hepatitis B, Haemophilus influenzae type 
b (Hib), rotavirus (RV) and pneumococcal conjugate vaccines (PCV). The impact of immunisation 
against these diseases is astonishing with estimates that 2-3 million deaths are prevented every year 
as a result of national vaccine programmes1. Vaccination works because the immune system engages 
defences against the antigenic components in the vaccine to produce a high quality, rapid and 
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specific immune response against the relevant pathogen. In addition to this specific effect, some 
researchers have argued that there are additional, non-specific effects of vaccines, beyond the direct 
protection against the diseases for which the vaccines were developed. 
These “non-specific effects” (NSE) of vaccines have also been termed “heterologous effects” or “off-
target effects”. The main outcome, which has been considered in epidemiological studies of the NSE 
of vaccines, is all-cause mortality with some authors concluding that, until a different vaccine is 
given, there are substantial additional reductions in all-cause mortality with live vaccines (such as 
oral polio vaccine (OPV), Bacillus Calmette–Guérin (BCG) and measles vaccines) and, conversely, 
increased all-cause mortality (in high mortality settings) with non-live vaccines (such as inactivated 
polio vaccine (IPV) and diphtheria tetanus & whole cell pertussis (DTP) combined vaccines). There is 
some evidence that these NSE on all-cause mortality are generally stronger in females than males 2. 
Furthermore, it is argued that, if the most recent vaccine received is a non-live vaccine, the non-
specific benefits obtained from a prior live vaccine are negated 3. The topic has been controversial, 
as much of the evidence is from studies with high risk of bias 4, has been addressed in few 
randomised controlled trials (RCTs) and arises from a limited range of settings (dominated by studies 
from Guinea Bissau). Furthermore, polarisation of views on the subject has complicated the 
assessment and unbiased interpretation of the existing data.  
Some findings relating to the NSE of vaccines, notably the association between some live vaccines 
and a pro-inflammatory protective state, are immunologically compelling. In addition, a large 
number of animal studies support a beneficial effect of BCG in enhancing the immune response to 
unrelated pathogens 5. It is plausible that a vaccine given shortly after birth, such as BCG, may 
influence the developmental trajectory of the immune system during a critical window of 
maturation. However, if NSE do occur as a result of vaccination later in infancy and have an 
important impact on mortality, it seems likely that the many other unpredictable bacterial and viral 
infections of early childhood, especially in settings with a high infectious burden, would also have 
non-specific effects on morbidity and mortality. With this in mind, it might be argued that NSE would 
be overwhelmed by greater exposure to these other pathogens than to the vaccines themselves. 
Furthermore, in observational studies, other differences between the populations who receive the 
vaccine(s) of interest and those who do not (such as healthcare-seeking behaviour) may increase the 
risk of bias.  
In 2016, a systematic review by Higgins et al., commissioned by the World Health Organization, was 
published 6 which attempted to evaluate whether there was evidence to support a change in the EPI 
programme as a result of NSE of vaccines with reference to BCG, DTP and measles vaccines. The 
findings of this review are briefly reviewed below. WHO concluded that there was insufficient 
evidence to support changes to current global immunisation policy7. 
BCG 
In Higgins et al’s systematic review, vaccination with BCG was shown to be associated with a 
reduction in all-cause mortality of around 50%, substantially greater than anticipated from 
prevention of tuberculosis alone. This was the case both in two RCTs in low birth weight infants 
considered at low risk of bias (relative risk (RR) 0.52, 95% confidence intervals (CI) 0.33 to 0.82), in 
two RCTs conducted in Native American children in the 1930s and 40s, and in nine observational 
studies considered at high risk of bias (RR 0.47, 95% CI 0.32 to 0.69) 6. There was no difference in the 
effect between boys and girls, and the benefit seemed to decrease with age. Other recent studies 
have suggested a beneficial effect of BCG vaccination on reducing (non-tuberculosis) respiratory 
infections. A population-based analysis from 33 countries over 25 years showed that BCG-vaccinated 
children had a 17-37% lower risk of acute lower respiratory tract infections 8. Similarly, a large 
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retrospective observational study from Spain found that there was a 40% lower rate of 
hospitalisation for respiratory infections and 36% decrease in sepsis admissions among BCG-
vaccinated children, but the vaccinated and control groups were from different regions and it was 
not possible to control for confounding 9.  
Whilst it is plausible that BCG prevents a substantial proportion of non-tuberculous infant deaths in 
certain settings, it is not clear how this observation is affected by the particular strain of BCG used10 
11 (several different vaccine strains are used around the world), timing of immunisation (BCG is given 
from birth to several months of age), or to survival of term infants born in different geographic 
regions. Follow-up duration in studies was typically short and it is not possible to assess whether the 
described effects persist beyond the first year of life. If beneficial NSE are induced by BCG, 
vaccination may be especially important in the neonatal period in high mortality settings where 
many deaths occur in the first month of life.  
It seems less likely that there are profound NSE associated with BCG vaccination in low mortality 
settings: in a recent RCT in Denmark, no reductions in hospitalisation for somatic acquired disease or 
parent-reported infection was documented in the first year of life amongst those who were 
randomised to receive BCG when compared with controls 12. However, in a pre-specified subgroup 
analysis, neonatal BCG vaccination may have reduced infections in the first three months of life in 
children whose mothers were BCG-vaccinated13. There therefore remains uncertainty about the 
importance and applicability of the NSE of BCG in different populations today. Further research, 
especially on impact in the neonatal period in low-income settings, where mortality from sepsis is 
high, might lead to the strengthening of recommendations for neonatal doses of BCG vaccine in 
some countries. The significance of NSE of BCG vaccination are also of potential importance for new 
tuberculosis vaccines designed to replace BCG and for decisions in relation to the discontinuation of 
routine BCG vaccination in countries where the decreasing incidence of tuberculosis no longer 
justifies its use for its specific effects. 
Measles 
Four RCTs which considered all-cause mortality following measles vaccine and 18 observational 
studies were included in the systematic review 6. The observational studies indicated a substantial 
reduction in all-cause mortality following measles vaccine (RR 0.51, 95% CI 0.42 to 0.63) but all were 
considered at high risk of bias. The evidence from the RCTs was not statistically significant (RR 0.74, 
95% CI 0.51 to 1.07). Observed effects were greater in girls than in boys. Although the data on NSE 
of measles vaccine remain uncertain from the available studies, if measles vaccine does have 
beneficial NSE, vaccination may be an important contributor to mortality reduction in young children 
in low-income settings. Mina et al 14 have suggested that, following recovery from measles, there is 
temporary loss of immune memory and a consequent increased risk of mortality. They modelled 
epidemiological and immunological data and found that, when measles was common, almost 50% of 
infection-related deaths in childhood could be attributed to a prolonged post-measles disease 
immunosuppressive effect. Since measles vaccine prevents measles, and therefore the post-measles 
infectious mortality, vaccination would have benefits beyond prevention of measles itself. 
Interestingly, this study indicates an overall effect size similar to that seen in the systematic review 
of the evidence for NSE. WHO currently advises measles vaccination after 9 months of age and the 
data currently available did not provide evidence for a change in global policy. If NSE are as 
important as some of the data summarised above suggest, earlier immunisation might further 
reduce mortality before 9 months of age. However, since maternal antibodies influence the immune 
response in younger infants and since the size and duration of the measles antibody response 
induced by the vaccine increases with age and immunological maturity independently of maternal 
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antibody effects, with earlier immunisation measles protection could be compromised leading to an 
overall increase in measles and post-measles mortality. 
Diphtheria, tetanus and pertussis 
Diphtheria, tetanus and pertussis are important contributors to child mortality in the absence of 
vaccination, with one recent analysis from the Netherlands indicating that 5.3% of all childhood 
deaths were attributable to these diseases in that country in the pre-vaccine era 15. The systematic 
review by Higgins et al found no RCTs that evaluated the effect of DTP vaccination on all-cause 
mortality 6. Ten observational studies were analysed, all of which were considered to have high risk 
of bias, finding an apparent increased mortality rate with an average RR of 1.38 but with 95% CIs 
that crossed 1.0 (0.92 to 2.08). Subsequently, Higgins et al acknowledged concerns with one of the 
included studies; with this study excluded, and the use of a random effects meta-analysis, their 
estimate of the RR of mortality for DTP is 1.53 (95% CI 1.02 to 2.30)6. Most of the studies included 
had an observation period of less than 8 months. Of the ten, two (including the study with major 
concerns about its bias) found an overall protective effect, one showed no apparent effect of the 
vaccine on all-cause mortality, and most did not find evidence of a difference between males and 
females. Mina et al 14, in the analysis mentioned above, also analysed whether pertussis disease had 
any effect on non-pertussis mortality and were not able to show any relationship. The implications 
of these findings are limited by a dearth of high quality studies. Furthermore, an increasing 
proportion of children in low-income settings are now immunised with the pentavalent vaccines 
(DTP combined with hepatitis B and Hib) and many with schedules that include other vaccines such 
as PCV and RV, all of which could modify any NSE. WHO concluded that the available evidence does 
not support any global immunisation policy changes. This conclusion has provoked heated debate. 
Concern has been raised about the selection of studies included in the review, and the suggestion 
that bias may have contributed to the findings in observational studies has been disputed 16. 
Protagonists of deleterious NSE of DTP argue that biases in observational studies ought not to 
operate in opposite directions for different vaccines and that frailty bias (where clinics do not 
vaccinate a child who is sick) would tend to reduce any apparent adverse effects of DTP. Conversely, 
antagonists point out that reaching conclusions from non-randomised studies is unsafe and that 
existing data are not sufficiently robust to drive changes in policy. The polarised views about the NSE 
of DTP can only be resolved by randomised trials done in relevant low-income settings. Design of 
studies of the NSE of vaccines is currently being considered by WHO.  
Polio 
A recent RCT evaluated the effect of a birth dose of OPV on all-cause mortality in Guinea Bissau and 
found no statistically significant effect of the vaccine on mortality (hazard ratio 0.83; 95% CI 0.61-
1.13) 17. Various sub-analyses found some evidence of significant NSE, particularly if the vaccine was 
given early, but this study does not provide conclusive evidence for an effect of OPV in reducing all-
cause mortality. Since OPV can cause vaccine-associated paralytic poliomyelitis (VAPP) and live polio 
viruses are currently being eradicated globally, live OPVs will be progressively replaced by IPV in the 
years ahead as part of the global polio eradication plan. 
Rabies 
A hypothesis has recently been proposed to explain higher numbers of cases of meningitis of 
different aetiologies and of cerebral malaria among children receiving the RTS,S malaria vaccine than 
in controls who received (non-live) rabies vaccine in a recent large RCT 18. Specifically, it has been 
suggested that, rather than the result of chance, or of a rare adverse effect of the RTS,S vaccine, 
these findings might be attributable to protective NSE of rabies vaccine 18 19. A small number of 
observations in animal studies support this theory, which might be explained by superantigenic 
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properties of the rabies nucleoprotein. Further experimental studies are needed to explore the 
plausibility of this idea, which, if proven, would be an example of beneficial NSE of non-live vaccine 
antigens. 
Sex 
An important aspect of NSE has been the apparent differences between the size of effects in male 
and female infants. Differences between sexes in the immune responses to vaccines are well-
recognised with females generally, although not in all studies or for all antigens, making stronger 
specific antibody responses than males 20-23. Hormonal differences may explain this in part, since sex 
hormone receptors are found on cells of the immune system 22. A study of yellow fever vaccine 
showed greater gamma-interferon pathway gene upregulation in women than men in the first 10 
days after vaccination 24. It is therefore plausible that there are clinically relevant differences 
between male and female infants in NSE, although any impact of these on survival, and thus 
implications for immunisation policy remain uncertain.  
An immunological basis for non-specific effects of vaccines 
Since Edward Jenner’s experiments with cowpox that led to the birth of vaccination, it has become 
widely understood that administration of an attenuated or inactivated bacterium, virus or 
components of a pathogen can lead to induction of specific immunity to that organism that will 
protect the individual on subsequent exposure and may also reduce spread of infection and thus 
provide herd protection. Since Jenner’s time, considerable advances have been made in the 
understanding of the generation of antigen-specific immunity and, more recently, the initial 
engagement of the innate immune system (following recognition of “danger signals” such as 
bacterial surface products or DNA), which promote the induction of adaptive T and B cell immunity. 
While the adaptive immune response is highly specific to the immunising agent or closely related 
antigenic structures, the early or innate immune response is more promiscuous. For example, 
interferon-alpha produced in response to a viral infection makes cells more resistant to subsequent 
infection by another viral agent. It is well-recognised that the nature of the initial innate response 
can determine the character and outcome of an immune response, a fact that has been harnessed in 
the development of vaccine adjuvants to enhance and direct protective responses with new 
vaccines. In addition, vaccine components with superantigenic properties, which can induce 
polyclonal T cell activation and T cell bystander effects provide additional known mechanisms which 
could theoretically result in NSE.  The existence of such non-specific immunological effects (NSIE) are 
central to contemporary understanding in immunology. Furthermore, both infectious diseases and 
vaccines induce epigenetic changes which may affect the subsequent behaviour of cells involved in 
the immune response 25.  
The most compelling evidence for NSIE with importance for protection against infectious diseases 
comes from a number of studies in animals over the last half century which have shown that there is 
T cell dependent resistance to unrelated pathogens which can be induced in mice 5 25. For example, 
mice that were latently infected with gamma-herpes virus developed prolonged production of 
gamma-interferon, macrophage activation and were resistant to infection with listeria or yersinia 26. 
Similarly, mice infected with Brucella abortus were resistant to listeria infection, with resistance 
correlating with macrophage phagocytic activity, although, in these elegant experiments, it is 
noteworthy that resistance was short-lived (demonstrated at day 18 after brucella infection but not 
present at day 4 or day 35) 27. BCG vaccination protects mice against murine malaria 28 and also 
induces protection against both candida 29 and schistosoma 30 infection which is independent of T 
and B cell activity. While the mechanisms of resistance are not clear, there is evidence that 
epigenetic modifications occur as a result of exposure to some bacterial and fungal products. 
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‘Trained immunity’, the concept that epigenetic reprogramming can enhance the innate immune 
response to reinfection, has been proposed as a mechanism that might be involved in NSE 31. One 
study found that increased production of pro-inflammatory cytokines by human NK cells was still 
present 3 months after BCG vaccination 32.  
Such studies in humans, linking disease endpoints to NSIE observations, are lacking and it is not 
currently possible to determine whether induction of particular cell types, cytokines or other 
mediators will improve clinical outcomes. In a recent review of immunological data that were 
available from studies of infants following BCG, DTP or measles vaccination, formal meta-analysis 
was not possible due to the heterogeneity in study design 33.  
In this systematic analysis of NSIE, undertaken as part of the WHO’s review of NSE, increased 
production of gamma-interferon after BCG vaccine was the most consistent finding in various in vitro 
experimental conditions, although some studies showed no effect 33.  Overall, the findings, though 
highly variable, were in line with observations in animal studies that BCG vaccine induces a more 
pro-inflammatory state. It is unclear whether this translates to increased resistance to future 
infection and it is not clear how long such effects might last or whether they can be consistently 
induced in routine vaccine programmes. 
Some consistent immunological effects have been identified following measles vaccination with a 
few studies showing increases in various cytokines while others showed no effect or even 
diminished responses. Interferon-gamma production in vitro was increased in some studies but 
unaffected or reduced in others. In vitro lymphoproliferation was increased after measles 
vaccination in response to candida and tetanus antigens and in some unstimulated cultures. The 
implications of these findings are unknown. 
There have been few immunological studies addressing DTP or its components and there were no 
consistent findings. One study found an increase in production of IL-5 and another found an increase 
in gamma-interferon production following stimulation of cell cultures. Several studies reported 
increases in unrelated IgG antibody levels (eg. serotype 14 pneumococcal antibody). These findings 
are difficult to interpret. 
Studies of NSIE in humans indicate that there may be some measurable changes in cytokine 
production, lymphocyte activation or cell numbers following vaccination but, for the present, it is 
not possible to determine from the literature whether such effects can be consistently induced, 
when they can be expected to occur, for how long they persist or, indeed, whether they have any 
clinical consequences.  
The live vs non-live vaccine hypothesis 
Since beneficial NSE have been attributed to BCG and measles vaccines, it has been proposed that 
live vaccines may have particular properties, beyond target disease prevention, which reduce infant 
mortality, whereas non-live vaccines may do the opposite 2 3 16. A number of live organisms and live-
attenuated vaccines induce production of pro-inflammatory cytokines (the most studied is gamma-
interferon as discussed above), which could, in turn, direct enhanced innate immune protection as 
described in various animal studies. However, this is likely to be an over simplification as there is 
wide variation in induction of pro-inflammatory responses by different live organisms. Indeed, non-
live organisms, vaccines and adjuvants can also induce inflammatory cytokine responses. Perhaps 
the most interesting concept here is the “setting of the thermostat” idea, that a birth dose of BCG 
may better set the immune system, perhaps through epigenetic changes, to produce protective 
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responses when challenged by infection in the subsequent months 34. This idea requires 
investigation in clinical trials.  
Conclusions 
Current immunobiological perspectives and the widespread use of vaccine adjuvants to stimulate 
the innate immune system and enhance vaccine immunogenicity are evidence that there can be 
NSIE of vaccines, even though our understanding of the importance, magnitude and duration of 
impact remains inadequate. In particular, interventions designed to augment non-specific resistance 
to life-threatening infections during the first few vulnerable months of life, particularly in high 
mortality settings, merit further investigation. Improved understanding of these effects is also 
fundamental for the future development of improved, safe and less reactogenic vaccines and so 
remains an important area for research. It is important to note here that the mechanisms underlying 
the specific effects of many vaccines remain poorly understood, including, for example, BCG 
vaccine’s protective effect against tuberculosis. 
The potential for adding benefit to current vaccine programmes by reducing mortality beyond the 
targeted diseases is clearly a worthy goal. In this context it is worth noting that the importance of 
‘indirect effects’ of vaccines – where high vaccine coverage decreases transmission with reduced 
incidence of target diseases in unimmunised as well as immunised individuals – is universally 
acknowledged. Also, it is known that one infection can predispose to another, for example, measles 
as discussed above, influenza and bacterial pneumonias, and varicella and invasive group A 
streptococcal disease. Therefore, beneficial effects of vaccines beyond the target pathogens are also 
likely to occur by virtue of these mechanisms. 
Although the WHO concluded that the currently available evidence is not sufficiently strong to drive 
changes in current global immunisation policy, the results of the systematic review by Higgins et al 
demonstrate the compelling need for new data to assess the importance of NSE from high-quality 
trials comparing the effects of different sequences of vaccinations on all-cause mortality. Generation 
of better evidence will be challenging both logistically and financially as a result of the difficulty of 
conducting sufficiently large and complex studies in the most resource poor settings.  
Assuming global mortality in early childhood continues to fall as a result of economic development, 
vaccination, improved nutrition and provision of clean water, the potential impact of NSE of vaccines 
could diminish. However, some regions will doubtless continue to suffer considerable infectious 
mortality over the next few decades and all efforts to maximise the benefits of vaccination, including 
investigation of the potential of beneficial NSE, should continue. 
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